| 1 |
34265801 |
10.1097/PAS.0000000000001780 |
2022 |
Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation. |
EP300 |
| 2 |
34560683 |
10.1097/PAS.0000000000001813 |
2022 |
A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients. |
EP300 |
| 3 |
34649275 |
10.1182/bloodadvances.2021005316 |
2022 |
Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity. |
EP300 |
| 4 |
35054466 |
10.3390/life12010073 |
2022 |
The Pathologic and Genetic Characteristics of Extranodal NK/T-Cell Lymphoma. |
EP300 |
| 5 |
35205765 |
10.3390/cancers14041018 |
2022 |
Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study. |
EP300 |
| 6 |
35317330 |
10.14740/wjon1436 |
2022 |
Non-GCB Diffuse Large B-Cell Lymphoma With an Atypical Disease Course: A Case Report and Clinical Exome Analysis. |
EP300 |
| 7 |
35646048 |
10.3389/fgene.2022.878618 |
2022 |
Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System. |
EP300 |
| 8 |
35908982 |
10.1016/j.blre.2022.100992 |
2022 |
Follicular lymphoma: The long and winding road leading to your cure? |
EP300 |
| 9 |
32273478 |
10.3324/haematol.2020.251579 |
2021 |
Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma. |
EP300 |
| 10 |
33399078 |
10.1016/j.esmoop.2020.100012 |
2021 |
Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence. |
EP300 |
| 11 |
33413063 |
10.2174/1568009620666210106122750 |
2021 |
Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL). |
EP300 |
| 12 |
33431788 |
10.1038/s41392-020-00437-8 |
2021 |
CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis. |
EP300 |
| 13 |
33560380 |
10.1182/bloodadvances.2020002469 |
2021 |
Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features. |
EP300 |
| 14 |
33829512 |
10.1111/his.14378 |
2021 |
Bcl-2-negative IGH-BCL2 translocation-negative follicular lymphoma of the thyroid differs genetically and epigenetically from Bcl-2-positive IGH-BCL2 translocation-positive follicular lymphoma. |
EP300 |
| 15 |
33911074 |
10.1038/s41419-021-03695-8 |
2021 |
Genome-wide CRISPR screens reveal synthetic lethal interaction between CREBBP and EP300 in diffuse large B-cell lymphoma. |
EP300 |
| 16 |
33951889 |
10.3324/haematol.2020.271957 |
2021 |
MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. |
EP300 |
| 17 |
34272731 |
10.1111/bjh.17708 |
2021 |
EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features. |
EP300 |
| 18 |
35008340 |
10.3390/cancers14010176 |
2021 |
Recent Advances in the Genetic of MALT Lymphomas. |
EP300 |
| 19 |
35071240 |
10.3389/fcell.2021.805195 |
2021 |
Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies. |
EP300 |
| 20 |
31423576 |
10.1111/bjh.16159 |
2020 |
M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy. |
EP300 |
| 21 |
31752573 |
10.1080/10428194.2019.1691200 |
2020 |
New murine models of aggressive lymphoma. |
EP300 |
| 22 |
31822509 |
10.1074/jbc.RA119.008742 |
2020 |
Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma. |
EP300 |
| 23 |
32012328 |
10.1002/hon.2718 |
2020 |
High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas. |
EP300 |
| 24 |
32553609 |
10.1016/j.virusres.2020.198066 |
2020 |
p300 promotes cell proliferation through suppressing Kaposi's sarcoma-associated herpesvirus (KSHV) reactivation in the infected B-lymphoma cells. |
EP300 |
| 25 |
32576962 |
10.1038/s41375-020-0908-8 |
2020 |
CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas. |
EP300 |
| 26 |
32882003 |
10.1182/bloodadvances.2020001879 |
2020 |
Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734. |
EP300 |
| 27 |
33045225 |
10.1016/j.humpath.2020.09.014 |
2020 |
The molecular landscape and other distinctive features of primary cutaneous follicle center lymphoma. |
EP300 |
| 28 |
33097085 |
10.1186/s13148-020-00948-9 |
2020 |
Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma. |
EP300 |
| 29 |
33160401 |
10.1186/s13148-020-00962-x |
2020 |
Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma. |
EP300 |
| 30 |
30307363 |
10.1080/15384047.2018.1523857 |
2019 |
Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL). |
EP300 |
| 31 |
30721949 |
10.1093/carcin/bgz013 |
2019 |
Mutational landscape of T-cell lymphoma in mice lacking the DNA mismatch repair gene Mlh1: no synergism with ionizing radiation. |
EP300 |
| 32 |
30733272 |
10.3324/haematol.2018.207928 |
2019 |
Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma. |
EP300 |
| 33 |
30979734 |
10.1158/1078-0432.CCR-18-3989 |
2019 |
Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas. |
EP300 |
| 34 |
31182547 |
10.1158/0008-5472.CAN-18-3622 |
2019 |
CBP/p300 Drives the Differentiation of Regulatory T Cells through Transcriptional and Non-Transcriptional Mechanisms. |
EP300 |
| 35 |
31221981 |
10.1038/s12276-019-0230-6 |
2019 |
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism. |
EP300 |
| 36 |
31292115 |
10.1182/blood.2019001126 |
2019 |
Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. |
EP300 |
| 37 |
31475375 |
10.1002/hon.2674 |
2019 |
m7FLIPI and targeted sequencing in high-risk follicular lymphoma. |
EP300 |
| 38 |
31489524 |
10.1007/s11899-019-00541-9 |
2019 |
Chromatin-Remodeled State in Lymphoma. |
EP300 |
| 39 |
31519498 |
10.1016/j.immuni.2019.08.006 |
2019 |
Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma. |
EP300 |
| 40 |
31533053 |
10.1016/j.immuni.2019.08.018 |
2019 |
Scoring a HAT-Trick against Lymphoma. |
EP300 |
| 41 |
31662917 |
10.1155/2019/4532434 |
2019 |
An Unusually Short Latent Period of Therapy-Related Myeloid Neoplasm Harboring a Rare MLL-EP300 Rearrangement: Case Report and Literature Review. |
EP300 |
| 42 |
31669559 |
10.1016/j.exphem.2019.10.004 |
2019 |
Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies. |
EP300 |
| 43 |
29305415 |
10.3324/haematol.2017.182444 |
2018 |
Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified. |
EP300 |
| 44 |
29359884 |
10.1002/ajmg.a.38603 |
2018 |
Benign and malignant tumors in Rubinstein-Taybi syndrome. |
EP300 |
| 45 |
29467311 |
10.1128/JVI.02155-17 |
2018 |
Epstein-Barr Virus Nuclear Antigen Leader Protein Coactivates EP300. |
EP300 |
| 46 |
29884215 |
10.1186/s13072-018-0197-x |
2018 |
CREBBP/EP300 bromodomains are critical to sustain the GATA1/MYC regulatory axis in proliferation. |
EP300 |
| 47 |
30104217 |
10.1182/blood-2018-01-824607 |
2018 |
North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies. |
EP300 |
| 48 |
30134235 |
10.1159/000492835 |
2018 |
Frequent Mutations in Natural Killer/T Cell Lymphoma. |
EP300 |
| 49 |
30227405 |
10.1159/000491013 |
2018 |
Microarray-Based Gene Expression Analysis Identifies Potential Diagnostic and Prognostic Biomarkers for Waldenström Macroglobulinemia. |
EP300 |
| 50 |
30360879 |
10.1053/j.seminoncol.2018.07.005 |
2018 |
New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs. |
EP300 |
| 51 |
30723478 |
10.3389/fimmu.2018.03135 |
2018 |
CVID-Associated Tumors: Czech Nationwide Study Focused on Epidemiology, Immunology, and Genetic Background in a Cohort of Patients With CVID. |
EP300 |
| 52 |
27742770 |
10.3324/haematol.2016.144964 |
2017 |
Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. |
EP300 |
| 53 |
28103279 |
10.1371/journal.pone.0170282 |
2017 |
Aristaless Related Homeobox (ARX) Interacts with β-Catenin, BCL9, and P300 to Regulate Canonical Wnt Signaling. |
EP300 |
| 54 |
28106467 |
10.1080/15592294.2017.1282587 |
2017 |
Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations. |
EP300 |
| 55 |
28302137 |
10.1186/s13045-017-0438-7 |
2017 |
Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort. |
EP300 |
| 56 |
28551630 |
10.21873/anticanres.11646 |
2017 |
Expression and Prognostic Significance of <i>EP300</i>, <i>TP53</i> and <i>BAX</i> in Clear Cell Renal Cell Carcinoma. |
EP300 |
| 57 |
28725161 |
10.1186/s12935-017-0439-1 |
2017 |
EP300 single nucleotide polymorphism rs20551 correlates with prolonged overall survival in diffuse large B cell lymphoma patients treated with R-CHOP. |
EP300 |
| 58 |
28831000 |
10.1073/pnas.1619555114 |
2017 |
Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth. |
EP300 |
| 59 |
29222279 |
10.1182/asheducation-2017.1.358 |
2017 |
Follicular lymphoma: are we ready for a risk-adapted approach? |
EP300 |
| 60 |
29340061 |
10.18632/oncotarget.22799 |
2017 |
Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets. |
EP300 |
| 61 |
26698557 |
10.2217/epi.15.96 |
2016 |
Epigenetic dysregulation in follicular lymphoma. |
EP300 |
| 62 |
27003102 |
10.3109/10428194.2016.1160083 |
2016 |
Evidence for an oncogenic modifier role for mutant histone acetyltransferases in diffuse large B-cell lymphoma. |
EP300 |
| 63 |
27132507 |
10.1038/onc.2016.126 |
2016 |
FOXO1 is a TXN- and p300-dependent sensor and effector of oxidative stress in diffuse large B-cell lymphomas characterized by increased oxidative metabolism. |
EP300 |
| 64 |
26192917 |
10.1038/ng.3358 |
2015 |
Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma. |
EP300 |
| 65 |
26256760 |
10.1016/S1470-2045(15)00169-2 |
2015 |
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. |
EP300 |
| 66 |
26473533 |
10.1038/bcj.2015.89 |
2015 |
Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas. |
EP300 |
| 67 |
24345752 |
10.1182/blood-2013-10-531509 |
2014 |
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. |
EP300 |
| 68 |
24529102 |
10.1186/1476-4598-13-29 |
2014 |
Histone acetyltransferase-deficient p300 mutants in diffuse large B cell lymphoma have altered transcriptional regulatory activities and are required for optimal cell growth. |
EP300 |
| 69 |
24942943 |
10.3960/jslrt.54.23 |
2014 |
Molecular pathogenesis of follicular lymphoma. |
EP300 |
| 70 |
25088465 |
10.1016/j.mce.2014.07.020 |
2014 |
Reciprocal occupancy of BCL6 and STAT5 on Growth Hormone target genes: contrasting transcriptional outcomes and promoter-specific roles of p300 and HDAC3. |
EP300 |
| 71 |
25364581 |
10.7497/j.issn.2095-3941.2014.03.006 |
2014 |
The gene expression patterns of BMPR2, EP300, TGFβ2, and TNFAIP3 in B-Lymphoma cells. |
EP300 |
| 72 |
23985173 |
10.1186/1755-8166-6-34 |
2013 |
Characterization of a case of follicular lymphoma transformed into B-lymphoblastic leukemia. |
EP300 |
| 73 |
22116549 |
10.1038/leu.2011.340 |
2012 |
Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy. |
EP300 |
| 74 |
22287508 |
10.18632/oncotarget.436 |
2012 |
Histone modification defects in developmental disorders and cancer. |
EP300 |
| 75 |
22585168 |
10.1158/2159-8290.CD-11-0208 |
2012 |
Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. |
EP300 |
| 76 |
23342264 |
10.1002/cam4.29 |
2012 |
MicroRNA-142 is mutated in about 20% of diffuse large B-cell lymphoma. |
EP300 |
| 77 |
24371765 |
10.1016/j.lrr.2012.10.002 |
2012 |
Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones. |
EP300 |
| 78 |
21232847 |
10.1016/j.canlet.2010.12.018 |
2011 |
A rearranged EP300 gene in the human B-cell lymphoma cell line RC-K8 encodes a disabled transcriptional co-activator that contributes to cell growth and oncogenicity. |
EP300 |
| 79 |
21390126 |
10.1038/nature09730 |
2011 |
Inactivating mutations of acetyltransferase genes in B-cell lymphoma. |
EP300 |
| 80 |
21796119 |
10.1038/nature10351 |
2011 |
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. |
EP300 |
| 81 |
19948376 |
10.1016/j.canlet.2009.10.018 |
2010 |
Histone acetyltransferase p300 is a coactivator for transcription factor REL and is C-terminally truncated in the human diffuse large B-cell lymphoma cell line RC-K8. |
EP300 |
| 82 |
20101207 |
10.1038/onc.2009.498 |
2010 |
The HTLV-1 tax protein cooperates with phosphorylated CREB, TORC2 and p300 to activate CRE-dependent cyclin D1 transcription. |
EP300 |
| 83 |
21041953 |
10.1172/JCI42869 |
2010 |
BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. |
EP300 |
| 84 |
18245479 |
10.1158/0008-5472.CAN-07-0008 |
2008 |
BCL6 represses Smad signaling in transforming growth factor-beta resistance. |
EP300 |
| 85 |
19064921 |
10.1073/pnas.0810965105 |
2008 |
Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. |
EP300 |
| 86 |
16638200 |
NA |
2006 |
[Regulatory effect of curcumin on p300 and HDAC1 in B-NHL cells]. |
EP300 |
| 87 |
15943569 |
10.1089/aid.2005.21.273 |
2005 |
Human T lymphotropic virus type 1 accessory protein p12I modulates calcium-mediated cellular gene expression and enhances p300 expression in T lymphocytes. |
EP300 |
| 88 |
14668346 |
10.1074/jbc.M309485200 |
2004 |
Kaposi's sarcoma-associated herpesvirus-encoded vIRF-3 stimulates the transcriptional activity of cellular IRF-3 and IRF-7. |
EP300 |
| 89 |
14635047 |
10.1002/eji.200324061 |
2003 |
p300 cooperates with Smad3/4 and Runx3 in TGFbeta1-induced IgA isotype expression. |
EP300 |
| 90 |
12402037 |
10.1038/ng1018 |
2002 |
Acetylation inactivates the transcriptional repressor BCL6. |
EP300 |
Datasets
Models
